HPE HPE 85 – Spring 2017 - Page 13

Symposium report Issue 85 | Spring 2017 regardless of what technology they employ. Dr Alan Wilkinson alcohol has a vapour pressure of 4400 Pascals (Pa) whereas commonly-used cytotoxic drugs, including cyclophosphamide and fl uorouracil have vapour pressures of less than 0.01 Pa. “IPA is a solvent and does not behave like any hazardous dr ug”, said Dr Wilkinson. He concluded that 2-POE is a safe and suitable challenge agent for testing the containment performance of all CSTDs, Tevadaptor performance The next step was to test the ability of a CSTD to contain hazardous drug vapour, rather than a surrogate substance. Dr Wilkinson described a study that had been carried out in his laboratory in the UK. A CSTD (OnGuard/Tevadaptor) was used to reconstitute a vial of cyclophosphamide, as it would be when in routine use. The cyclophosphamide vial was placed in a water bath at 50°C inside a sealed glass chamber. This increases the vapour pressure of the drug above the normal (room temperature) value and provides a “really serious challenge to the OnGuard (Tevadaptor) technology and specifi cally the ToxiGuard vapour capture system”, said Dr Wilkinson. Nitrogen was fed into the vial at a rate of 300ml/min, via a 21-gauge needle inserted through the adaptor. The tip of the cannula was above the surface of the drug solution. The BSTL environmental test chamber as used to replicate the NIOSH test protocol for assessment of CSTD systems. 11 hospitalpharmacyeurope.com